JUBITEL (Telmisartan Tablets 40mg)

Country: Malasja

Lingwa: Ingliż

Sors: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Ingredjent attiv:

TELMISARTAN

Disponibbli minn:

HEALOL PHARMACEUTICALS SDN. BHD.

INN (Isem Internazzjonali):

TELMISARTAN

Unitajiet fil-pakkett:

3 x 10 Tablets

Manifatturat minn:

Jubilant Generics Limited

Fuljett ta 'informazzjoni

_CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP) _
JUBITEL (TELMISARTAN TABLETS 40MG & 80MG)
Telmisartan (40mg & 80mg)
1
WHAT IS IN THIS LEAFLET
1.
What JUBITEL is used for
2.
How JUBITEL works
3.
Before you use JUBITEL
4.
How to use JUBITEL
5.
While you are using it
6.
Side effects
7.
Storage and Disposal of
JUBITEL
8.
Product Description
9.
Manufacturer and Product
Registration Holder
10.
Date of revision
WHAT IS JUBITEL USED FOR
JUBITEL is used to treat high blood
pressure. It is also used to reduce
your risk of cardiovascular events
such as a heart attack, stroke or death
from cardiovascular causes in
patients 55 years or older at high risk
of developing major cardiovascular
events who are unable to take a
group of medicines called ACE
inhibitors.
JUBITEL can be used in additional
to other needed treatment such as for
blood pressure, anti-blood clotting or
cholesterol lowering therapy.
HOW JUBITEL WORKS
JUBITEL
works by blocking a
receptor called angiotensin II
receptor. Angiotensin II is a
substance produced in your body
which causes your blood vessels to
narrow, thus increasing your blood
pressure. Telmisartan blocks the
effect of angiotensin II so that the
blood vessels relax, and your blood
pressure is lowered.
BEFORE YOU USE JUBITEL
_-When you must not use it _
Do not use JUBITEL if you are
allergic to Telmisartan or any other
ingredients in this medication.
If you are more than 3 months
pregnant. It is best to avoid this
medication in early pregnancy.
If you have severe liver problems
such as cholestasis or biliary
obstruction (problems with drainage
of the bile from the liver and gall
bladder) or any other severe liver
disease.
If you are diabetic or have renal
(kidney) disease and are on a high
blood pressure medication called
Aliskiren.
If you are breastfeeding.
_-Before you start to use it _
Please tell your doctor if you are
suffering or have ever suffered from
any of the following conditions or
illnesses:

Kidney disease or kidney
transplant

Renal artery stenosis
(narrowing of the blood
ves

Karatteristiċi tal-prodott

Last modified: 1. November 2018, 11:48 AM
For the use of a registered medical practitioner or a hospital or a
laboratory only
JUBITEL
TELMISARTAN TABLETS
40 MG & 80 MG
PRODUCT NAME
Telmisartan Tablets 40 mg
Telmisartan Tablets 80 mg
NAME AND STRENGTH OF ACTIVE INGREDIENT
EACH TABLET CONTAINS:
FOR 40 MG:
Telmisartan Ph.Eur. 40 mg
FOR 80 MG:
Telmisartan Ph.Eur. 80 mg
PRODUCT DESCRIPTION
FOR 40 MG:
White to off white, capsule shaped tablets debossed with “H” on
one side and plain on the other side.
FOR 80 MG:
White to off white, oval shaped tablets debossed with “D” on one
side and plain on the other side.
PHARMACODYNAMICS / PHARMACOKINETICS
PHARMACOLOGICAL/CLINICAL PARTICULARS
Pharmacotherapeutic group: Angiotensin II Antagonists, plain, ATC
Code: C09CA07.
Mechanism of action
Telmisartan is an orally active and specific angiotensin II receptor
(type AT
1
) antagonist. Telmisartan displaces
angiotensin II with very high affinity from its binding site at the AT
1
receptor subtype, which is responsible for
the known actions of angiotensin II. Telmisartan does not exhibit any
partial agonist activity at the AT
1
receptor.
Telmisartan selectively binds the AT
1
receptor. The binding is long-lasting. Telmisartan does not show
affinity for
other receptors, including AT
2
and other less characterized AT receptors. The functional role of
these receptors
is not known, nor is the effect of their possible overstimulation by
angiotensin II, whose levels are increased
by telmisartan. Plasma aldosterone levels are decreased by
telmisartan. Telmisartan does not inhibit human
plasma renin or block ion channels. Telmisartan does not inhibit
angiotensin converting enzyme (kininase II),
the enzyme which also degrades bradykinin. Therefore it is not
expected to potentiate bradykinin-mediated
adverse effects.
In human, an 80 mg dose of telmisartan almost completely inhibits the
angiotensin II evoked blood pressure
increase. The inhibitory effect is maintained over 24 hours and still
measurable up to 48 hours.
Clinical efficacy a